drugset / Trial / NCT06937619
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
Timeline
- Start
- 2025-04-21
- Primary completion
- 2025-11-10
- Completion
- 2025-11-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risankizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.